The KEYNOTE-775 study confirms long-term benefits of Lenvatinib and Pembrolizumab for recurrent endometrial cancer, showing sustained survival rates and efficacy.
Advances in Endometrial Cancer: Updates on Lenvatinib Plus Pembrolizumab
Explore the effective management of recurrent endometrial cancer with lenvatinib and pembrolizumab, emphasizing patient education and multidisciplinary care.
Endometrial cancer treatment evolves with molecular insights, enhancing patient outcomes through tailored therapies and innovative clinical trials.
Recent studies highlight the effectiveness of lenvatinib and pembrolizumab in improving overall survival for patients with prior therapy in endometrial cancer.
Real-world data reinforces the efficacy and tolerability of lenvatinib and pembrolizumab for treating recurring endometrial cancer.
Ramez N. Eskander, MD, discusses the optimal use of lenvatinib/pembrolizumab in clinical practice for patients with endometrial cancer. He provides advice for integrating this regimen into the treatment paradigm.